CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of “Hold” from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned an average rating of “Hold” from the nineteen ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $78.38.

Several research firms have issued reports on CRSP. Bank of America dropped their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. JMP Securities restated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Chardan Capital restated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, January 14th.

CRISPR Therapeutics Trading Down 0.1 %

Shares of NASDAQ CRSP opened at $41.81 on Wednesday. The stock has a fifty day simple moving average of $44.09 and a two-hundred day simple moving average of $47.46. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $91.10. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of -14.77 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the prior year, the business posted ($1.41) earnings per share. Analysts forecast that CRISPR Therapeutics will post -5.13 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 30,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the transaction, the chief executive officer now directly owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. This trade represents a 13.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Kestra Private Wealth Services LLC grew its stake in shares of CRISPR Therapeutics by 1.5% during the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock valued at $812,000 after buying an additional 310 shares during the last quarter. Tyche Wealth Partners LLC bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $328,000. Western Pacific Wealth Management LP grew its stake in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the last quarter. Spire Wealth Management grew its stake in shares of CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after buying an additional 1,482 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of CRISPR Therapeutics by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,098 shares of the company’s stock valued at $712,000 after buying an additional 1,717 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.